logo-loader
viewG Medical Innovations Holdings Ltd

G Medical Innovations signs key agreements with US health service providers

The company continues to increase its market share and operations across the US in the lead up towards its proposed NASDAQ dual listing.

doctor and patient
New agreements are an opportunity to increase revenue

G Medical Innovations Holdings Ltd (ASX:GMV) has executed key provider participation agreements with Prime Health Services Inc (PHS) and Ancillary Care Services (ACS) in the US territory.

The agreement was made by G Medical’s wholly-owned subsidiary G Medical Diagnostic Services Inc (GMEDx).

GMEDx owns two Independent Diagnostic Testing Facility (IDTF) and Mobile Cardiac Telemetry (MCT) operations being, ‘Telerhythmics’ and ‘Cardiostaff’.

READ: G Medical Innovations acquires Telerhythmics, expands US footprint

The two operations have been successfully integrated with the synergies realising month on month growth in patient numbers.

With the addition of the new provider participation agreements (PPA), GMEDx has further increased its footprint in the healthcare delivery system of cardiac monitoring to provide more exposure to its future patient base and third-party payer populations.

READ: G Medical Innovations secures first US commercial orders valued at almost US$22 million

Obtaining additional access to Medicare reimbursements for services rendered to covered persons under the PPA with PHS and ACS will translate to increased revenue opportunity for GMEDx, as these services are carried out based on individual patient requirements, the treatment modalities utilised and term and frequency of treatment.

There is no immediate revenue impact from the PPAs, and the future revenue opportunity to GMEDx is subject to PHS’s and ACS’s individual patient requirements.

READ: G Medical Innovations advances mobile health technologies in March quarter

G Medical CEO Dr Yacov Geva said: “I am pleased to update our shareholders on the continued expansion of our footprint and relationships in the key US market.

“Our new partners are both long-standing and well-respected multi-faceted health service providers of the highest quality in this territory.

“Through this, we importantly continue to increase our market share and operations across the US in the lead up towards our proposed NASDAQ dual listing.”

Quick facts: G Medical Innovations Holdings Ltd

Price: 0.081 AUD

ASX:GMV
Market: ASX
Market Cap: $32.97 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of G Medical Innovations Holdings Ltd named herein, including the promotion by the Company of G Medical Innovations Holdings Ltd in any Content on...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Australian e-health company G Medical Innovations eyes Nasdaq listing

G Medical Innovations Holdings Ltd (ASX:GMV) CEO Yacov Geva sits down with Proactive Investors' Christine Corrado in New York to update investors on the mobile and e-health company's move to list on the Nasdaq. Geva says the company, which specializes in software and devices that aim to...

on 16/10/18

2 min read